October 15, 2010 represented the high price for the common stock of CardioGenics: $1.44... IMO, given the start of the Beta Site testing and the strong possibility that FDA approval of the POC analyzer will come during the first half of 2014 it is not unreasonable to predict that the high price will be tested sometime next year. The odds of a successful test increase significantly if there is a joint venture between CardioGenics and Siemens.